This week in cardiology from heartwire

View all posts »

#92: Revisiting dabigatran dose in the US?; terutroban no better than aspirin; polypill data predict halving of CV events; ticagrelor approved in Canada; rivaroxaban in secondary stroke prevention

Jun 3, 2011 15:30 EDT


For the week ending June 3, 2011 we discuss the following top cardiology news from heartwire:

 

And also, in brief:

 

Join us for a comprehensive review of this week's most important cardiology news.





« Previous Post
#93: Simvastatin 80 mg restricted by FDA; dabigatran cost-effectiveness depends on risk, INR control; FDA: No cancer risk with ARBs; SHARP on ezetimibe/simvastatin; systolic BP target in diabetes
Jun 10, 2011 14:40 EDT Next post »
#91: More controversy for ezetimibe; NIH stops AIM-HIGH; apixaban approved in Europe; DHA, EPA, and LDL cholesterol; high heart rate: Culprit or bystander in heart failure?
May 27, 2011 11:20 EDT



Your comments
#92: Revisiting dabigatran dose in the US?; terutroban no better than aspirin; polypill data predict halving of CV events; ticagrelor approved in Canada; rivaroxaban in secondary stroke prevention
# 1 of 1
September 1, 2011 05:14 (EDT)
Stroke Prevention
Neurcumin™ is a unique nutritional supplement formulated by leading physician Nasser Razack, MD, former Director of Neurointervention at the University of Michigan. It contains both natural anti-oxidants and anti-inflammatory agents which protect the brain by reducing free radical damage and inflammation. These properties make Neurcumin™ an unprecedented and excellent neuroprotective agent. The ingredients contained in Neurcumin™ are not only all natural, but are more powerful than many over-the-counter or prescribed medications with little or no side effects

You must be a member (with full membership) to post a comment.
Already a member?
Enter your login information below:
 Remember me on this computer
Forgot your username and/or password?
        Login        
Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

    Join now for full access